Log In Sign up
The largest database of trusted experimental protocols
> Anatomy > Cell > Peripheral Blood Stem Cells

Peripheral Blood Stem Cells

Peripheral blood stem cells are hematopoietic progenitor cells found circulating in the bloodstream.
These cells can be mobilized from the bone marrow and collected from the peripheral blood, then used for stem cell transplantation and regenerative medicine applications.
PubCompare.ai's AI-powered tools can help researchers optimize their peripheral blood stem cell research workflows by easily locating the best protocols and products from literature, pre-prints, and patents.
Improve your stem cell research today with PubCompare.ai.

Most cited protocols related to «Peripheral Blood Stem Cells»

1
Characterization of AC220-Resistant FLT3-ITD Mutations
MSCVpuroFLT3-ITD plasmid DNA was mutagenized and used to generated AC220-resistant Ba/F3 clones as previously described11 (link). The FLT3 kinase domain was sequenced from PCR-amplified genomic DNA isolated from AC220-resistant clones. Identified drug-resistant mutations were re-engineered into MSCVpuroFLT3-ITD using site-directed mutagenesis and Ba/F3 cell lines were created as detailed in Methods. Cell viability in the presence and absence of drug was assessed using trypan blue exclusion. FLT3 phosphorylation status was determined by western blot analysis of whole cell lysates prepared after 90 min of drug exposure from Ba/F3 cells stably expressing FLT3 mutant isoforms and from transfected 293T cells in the absence of drug. The FLT3 kinase domain was PCR amplified from cDNA derived from blood or bone marrow samples from patients enrolled on the exploratory portion of the phase II trial of AC220 in AML (http://clinicaltrials.gov/ct2/show/NCT00989261; identifier NCT00989261) and from normal control bone marrow or mobilized peripheral blood stem cells. PCR products were cloned into Escherichia coli and individual clones were sequenced using Sanger sequencing. Alternatively, SMRTBell libraries13 (link) were prepared as per the manufacturer's instructions and sequenced on a Pacific Biosciences RS instrument. For details of the computational sequencing analysis, please see Methods. Molecular docking of FLT3-ITD to AC220 was performed using Autodock 4.2 package. Inhibitor binding constants were measured using an active-site-dependent competition binding assay as previously descibed20 (link). For further details of methods, please see Methods.
Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., Perl A.E., Travers K.J., Wang S., Hunt J.P., Zarrinkar P.P., Schadt E.E., Kasarskis A., Kuriyan J, & Shah N.P. (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature, 485(7397), 260-263.
Publication 2012
Biological Assay BLOOD Bone Marrow Cell Lines Cells Cell Survival Clone Cells DNA, Complementary Escherichia coli FLT3 protein, human Genome HEK293 Cells Mutagenesis, Site-Directed Mutation Patients Peripheral Blood Stem Cells Pharmaceutical Preparations Phosphorylation Phosphotransferases Plasmids Protein Isoforms Sequence Analysis Trypan Blue Western Blot
2
Validation of Telomere Length in Severe Aplastic Anemia

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
BLOOD Donor, Blood Donors Ethics Committees, Research Grafts Marrow Patients Peripheral Blood Stem Cells Tissue Donors Transplantation Umbilical Cord Unrelated Donors Vascular Grafting
3
Isolation of Pathogen-Free Cord Blood Stem Cells
Human cord blood units derived from healthy donors were purchased from the Maternal and Child Health Hospital (Jinan, Shandong, China). All cord blood samples were screened for alanine aminotransferase and pathogenic antigen antibodies (including anti-HCV, anti-HBsAg, anti-HIV, and anti-syphilis Abs), and only pathogen-free cord blood units were used for isolating CB-SCs. Human cord blood-derived stem cells (CB-SC) were generated as previously described with the following modifications [14 (link),16 (link)]. Cord blood mononuclear cells were plated in serum-free culture medium (Lonza, Walkersville, MD) and incubated at 37°C, in 8% CO2. After 2 to 3 weeks, CB-SCs growing at 80% to 90% confluence were prepared for clinical trial. Endotoxin level was < 0.05 EU/ml.
Zhao Y., Jiang Z., Zhao T., Ye M., Hu C., Yin Z., Li H., Zhang Y., Diao Y., Li Y., Chen Y., Sun X., Fisk M.B., Skidgel R., Holterman M., Prabhakar B, & Mazzone T. (2012). Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Medicine, 10, 3.
Publication 2012
Alanine Transaminase Antibodies Antigens Children's Health Cone-Rod Dystrophy 2 Culture Media Donors Endotoxins Hepatitis B Surface Antigens Hepatitis C Antibodies Homo sapiens pathogenesis PBMC Peripheral Blood Mononuclear Cells Peripheral Blood Stem Cells Serum Syphilis Umbilical Cord Blood
4
HIV Gene Transduction in Stem Cells

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Cloning Vectors Cytokine Diabetes Mellitus Digestive System Ethics Committees, Research Fetal Bovine Serum Fibronectins Flow Cytometry flt3 ligand Granulocyte Colony-Stimulating Factor HIV-1 Homo sapiens Hyperostosis, Diffuse Idiopathic Skeletal Immunoglobulins Infection Kidney Diseases Macaca mulatta MG 132 Peripheral Blood Stem Cells Polybrene retronectin Serum Stem Cell Factor
5
Maraviroc Addition for GVHD Prophylaxis in HSCT
We performed a phase 1 and 2 single-group clinical trial to study the role of maraviroc when it was added to conventional GVHD prophylaxis after reduced-intensity conditioned HSCT for patients with hematologic cancers. The phase 1 portion was designed to confirm the safe dose level that was established in patients with HIV and to confirm consistent target drug levels in vivo. This dose was then used in the phase 2 portion of the study. Study participants included adult candidates for HSCT who met protocol eligibility criteria. We calculated the HSCT comorbidity index for each patient, as described previously.26 (link)From June 2009 through March 2011, we enrolled 38 patients. All eligible patients at our institution were offered the chance to participate. Enrollment was held during the analysis of safety and pharmacokinetic data in the phase 1 portion. All patients received a uniform conditioning regimen of intravenous fludarabine (120 mg per square meter of body-surface area) and busulfan (6.4 mg per kilogram of body weight), followed by the infusion of granulocyte colony-stimulating factor–mobilized peripheral-blood stem cells from either a related or an unrelated donor. A single-antigen HLA mismatch was allowed. We determined the amount of CD34+ and CD3+ cells in the graft using standard procedures.27 (link)All patients received standard GVHD prophylaxis with oral tacrolimus (0.06 mg per kilogram per day) in two divided doses starting 2 days before transplantation and intravenous methotrexate (15 mg per square meter on day 1 and 10 mg per square meter on days 3, 6, and 11). The dose of tacrolimus was adjusted to a target trough level of 5 to 15 ng per milliliter. All patients received antimicrobial prophylaxis, which typically included voriconazole and acyclovir starting 2 days before transplantation and trimethoprim–sulfamethoxazole starting at the time of engraftment.
Maraviroc was given orally twice daily starting 2 days before transplantation until day 30. Administration was suspended in cases of toxic effects that investigators considered to be related to the study drug or in cases of severe mucositis. Planned infusions of donor lymphocytes were not allowed. Donor lymphocyte infusion or chemotherapy could be administered to treat relapse or decreased chimerism levels at the discretion of the treating physician.
Reshef R., Luger S.M., Hexner E.O., Loren A.W., Frey N.V., Nasta S.D., Goldstein S.C., Stadtmauer E.A., Smith J., Bailey S., Mick R., Heitjan D.F., Emerson S.G., Hoxie J.A., Vonderheide R.H, & Porter D. (2012). Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease. The New England journal of medicine, 367(2), 135-145.
Publication 2012
Acyclovir Adult Antigens ARID1A protein, human Body Surface Area Body Weight Busulfan Cell Transplants Chimerism Donors Drug Delivery Systems Eligibility Determination fludarabine Granulocyte Colony-Stimulating Factor Hematologic Neoplasms Lymphocyte Maraviroc Methotrexate Microbicides Mucositis Patients Peripheral Blood Stem Cells Pharmacotherapy Physicians Relapse Safety Tacrolimus Transplantation Treatment Protocols Trimethoprim-Sulfamethoxazole Combination Unrelated Donors Voriconazole

Most recents protocols related to «Peripheral Blood Stem Cells»

1
In Vivo Therapeutic Vector Delivery
Not available on PMC !

Example 25

In a preferred embodiment, blood stem/progenitor cells, and target cells are transfected with the therapeutic vector(s) (or associated therapeutic virus) in vivo by introduction of the therapeutic vector(s) into the host blood, tissues, or bone marrow, etc. The greatest benefit may be achieved by modifying a large number of endogenous target and stem/progenitor cells. This may be accomplished by using an appropriately-sized, catheter-like device, or needle to inject the therapeutic vector(s) into the venous or arterial circulation. In a preferred embodiment, the virus is pseudotyped with VSV-G envelope glycoprotein and native HIV-1 env proteins.

US11859168B2. Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine (2024-01-02). None [US]. Inventors: Christopher B. Reid [US], Melissa Braga [US], Lilian N. Santamaria [US], Ashley N. Wickrema [US], Marinne D. Wickrema [US], Anthony Hao Dinh [US], Yaman Eksioglu [US], Mat Hoang Ho [US].
Patent 2024
Arteries BLOOD Bone Marrow Catheters Cells Cloning Vectors Gene Products, env Glycoproteins HIV-1 Medical Devices Needles Peripheral Blood Stem Cells Satellite Viruses Stem Cells Therapeutics Tissues Veins Virus
2
Extracting Hematopoietic Stem Cells from Blood
Not available on PMC !

Example 4

Extracting Haematopoietic Stem Cells from Peripheral Blood

Upon giving consent the donors are given a granulocyte-colony stimulating factor (G-CSF) and/or a granulocyte-macrophage colony-stimulating factor (GM-CSF), e.g. Neupogen® (commercially available from Amgen Inc. USA) to help harvest peripheral haematopoietic stem cells with minimal possible discomfort to donors. Cell surface polypeptide markers are used for identifying long-lasting multipotent stem-cells. Suitably markers may include CD 34+, CD59+, Thy1+, CD38low/−, C-kit−/low, and lin−.

US11878033B2. Cancer-killing cells (2024-01-23). LIFT BIOSCIENCES LTD [GB]. Inventors: Alex Blyth [GB], Nico Bruyniks [GB].
Patent 2024
Blood Cells CD59 protein, human Cells Donors Granulocyte-Macrophage Colony-Stimulating Factor Granulocyte Colony-Stimulating Factor Hematopoietic System Malignant Neoplasms Multipotent Stem Cells Neupogen Peripheral Blood Stem Cells Polypeptides Proto-Oncogene Protein c-kit Stem Cells, Hematopoietic
3
Isolating Menstrual Blood-Derived Stem Cells
MenSCs were provided by the Innovative Precision Medicine (IPM) Group, and the specific process of obtaining cells was as above [37 (link), 47 (link), 48 (link)]. In brief, menstrual blood samples were collected from healthy young women (n = 3) aged 20 to 30 years during menstruation using Divacup (Kitchener, ON). Fresh menstrual blood samples should not be stored for more than 72 hours in a storage solution containing kanamycin sulfate, cefadroxil, vancomycin hydrochloride, amphotericin B, gentamicin sulfate, and heparin in a 4°C refrigerator. Stem cells in menstrual blood were obtained by density gradient centrifugation with Ficoll-Hypaque (DAKEWE, China). The isolated interlayer cells were cultured in Minimum Essential Medium α (MEMα) (Gibco, USA) adding 15% Australian fetal bovine serum (FBS). MenSCs were completely digested with 0.25% trypsin-EDTA (Fisher Scientific, USA) for 5 min, then neutralized with complete medium, and centrifuged to complete subculture. Passages 5-8 (p5-p8) of MenSCs can be used for collection of small EVs.
Xu H., Fu J., Chen L., Zhou S., Fang Y., Zhang Q., Chen X., Yuan L., Li Y., Xu Z, & Xiang C. (2023). TNF-α Enhances the Therapeutic Effects of MenSC-Derived Small Extracellular Vesicles on Inflammatory Bowel Disease through Macrophage Polarization by miR-24-3p. Stem Cells International, 2023, 2988907.
Publication 2023
Amphotericin B BLOOD Cefadroxil Cells Centrifugation, Density Gradient Edetic Acid Fetal Bovine Serum Ficoll Heparin Hydrochloride, Vancomycin Hypaque Kanamycin Sulfate Menstruation Peripheral Blood Stem Cells Physiology, Cell Precision Medicine Sulfate, Gentamicin Trypsin Woman
4
Haploidentical HSCT for Children without Matched Donors
Children without a suitable closely HLA-matched related or unrelated donor (donors with more than nine out of 10 matching HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ loci), were eligible to receive haploidentical HSCT. High-resolution typing for HLA was conducted for both the patients and close family members for assessment of haploidentical-related donors, and an appropriate donor was selected according to an algorithm in our institute (16 (link)). Of the 25 patients, 19 received bone marrow (BM) and peripheral blood stem cells (PBSCs) as the stem cell sources, whereas six patients received only PBSCs due to the quarantine regulations for COVID-19. G-CSF (5 µg/kg per day; filgrastim) was used to mobilize the bone marrow (G-BM) and peripheral blood (G-PB). Both the G-BM (collected on day 0, after 4 days of G-CSF treatment) and G-PB (collected on day 1, after 5 days of G-CSF treatment) cells were collected.
Huang J., Hu G., Suo P., Bai L., Cheng Y., Wang Y., Zhang X., Liu K., Sun Y., Xu L., Kong J., Yan C, & Huang X. (2023). Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without Down syndrome in China: A single-center study. Frontiers in Oncology, 13, 1116205.
Publication 2023
BLOOD Bone Marrow Cells Child COVID 19 Donors Filgrastim Granulocyte Colony-Stimulating Factor HLA-B Antigens HLA-C Antigens HLA-DR Antigens Patients Peripheral Blood Stem Cells Quarantine Tissue Donors Unrelated Donors
5
Cellular Immunotherapy in Relapsed Transplant
In this study, C-DLI was defined as the infusion of lymphocytes additionally collected from an unstimulated donor who was the previous alloSCT donor, whereas G-DLI was defined as the infusion of remnant stem cells that were cryopreserved after the initial alloSCT without prophylactic immunosuppression conditioning [4 (link)]. Patients with remnant stem cells cryopreserved after previous alloSCT received G-DLI. The remaining peripheral blood stem cells from the initial alloSCT were cryopreserved − 190 °C, and these were the cell sources of G-DLI. Cryopreserved peripheral blood stem cells were thawed at 37 °C prior to infusion. The salvage chemotherapy for the relapsed patient was used per the attending physician’s decision. And patients with a history of immunosuppressant use before one month of relapse were included in the analysis.
Park W., Byun J.M., Hong J., Kim I., Shin D.Y., Park S., Koh Y, & Yoon S.S. (2023). Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation. Annals of Hematology, 102(3), 629-639.
Publication 2023
Condoms Immunosuppression Immunosuppressive Agents Lymphocyte Patients Peripheral Blood Stem Cells Pharmacotherapy Physicians Relapse Stem Cells Tissue Donors

Top products related to «Peripheral Blood Stem Cells»

1
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
2
Iscove modified dulbecco media (imdm) by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Germany, Canada, France, Italy, Austria, Israel, Switzerland, Belgium, Australia
IMDM (Iscove's Modified Dulbecco's Medium) is a cell culture medium formulated for the growth and maintenance of a wide variety of cell types, including hematopoietic cells. It provides a balanced salt solution and essential nutrients required for cell proliferation and survival.
3
L glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.
4
Anti cd34 coated magnetic beads by Miltenyi Biotec
Sourced in Germany
Anti-CD34-coated magnetic beads are a laboratory product designed to separate and isolate CD34-positive cells from biological samples. The beads are coated with antibodies specific to the CD34 antigen, which is expressed on the surface of hematopoietic stem and progenitor cells. These magnetic beads can be used in cell separation and purification procedures.
5
Tnf α by R&D Systems
Sourced in United States, United Kingdom, Germany, France, China, Japan, Sweden, Canada, Italy, Switzerland, Israel, Macao, Netherlands, Austria
TNF-α is a recombinant human tumor necrosis factor-alpha (TNF-α) protein. TNF-α is a key pro-inflammatory cytokine that plays a central role in the immune response and inflammatory processes.
6
Heat inactivated fbs by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, Canada, China
Heat-inactivated FBS is a type of fetal bovine serum that has been subjected to a heat treatment process to inactivate any potential contaminants or pathogens. This process helps to ensure the safety and quality of the serum for use in cell culture applications.
7
Rpmi 1640 by Eurobio Scientific
Sourced in France
RPMI 1640 is a widely used cell culture medium formulated to support the growth of a variety of cells, including human and animal cells. It provides a balanced combination of essential nutrients, vitamins, and salts to maintain cell viability and proliferation in vitro.
8
Heat inactivated by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Japan
Heat-inactivated is a laboratory equipment product used for thermal inactivation of biological samples. It provides a controlled environment to expose samples to heat, effectively deactivating or destroying specific biological components within the samples.
9
Mts assay by Promega
Sourced in United States, Italy, United Kingdom, China, Germany, Australia, Japan
The MTS assay is a colorimetric method used to assess cell viability and proliferation. The assay measures the reduction of a tetrazolium compound (MTS) to a colored formazan product, which is directly proportional to the number of living cells in culture. This provides a quantitative assessment of cell metabolic activity.
10
Spectra optia by Terumo BCT
Sourced in United States, Japan
The Spectra Optia is a cell separation system designed for therapeutic cell collection and processing. It is capable of performing procedures such as platelet, plasma, or mononuclear cell collection and exchange transfusion. The device utilizes centrifugation technology to separate and collect specific blood components.

More about "Peripheral Blood Stem Cells"

Peripheral blood stem cells (PBSCs) are a type of hematopoietic progenitor cell found circulating in the bloodstream.
These immature cells can be mobilized from the bone marrow and collected from the peripheral blood, making them a valuable resource for stem cell transplantation and regenerative medicine applications.
PBSCs are often used in conjunction with other key components and processes to optimize stem cell research and therapies.
For instance, Penicillin/streptomycin and L-glutamine are commonly added to cell culture media to prevent bacterial growth and support cell health.
IMDM (Iscove's Modified Dulbecco's Medium) is a widely used basal medium that provides essential nutrients for cell proliferation and differentiation.
Anti-CD34-coated magnetic beads can be utilized to isolate and enrich the population of PBSCs, which express the CD34 surface marker.
The cytokine TNF-α (Tumor Necrosis Factor-alpha) is known to stimulate the mobilization of PBSCs from the bone marrow into the peripheral blood.
To support the growth and expansion of PBSCs, researchers often supplement their culture media with Heat-inactivated Fetal Bovine Serum (Heat-inactivated FBS), which provides essential growth factors and nutrients.
RPMI 1640 is another commonly used basal medium that supports the cultivation of various cell types, including PBSCs.
The MTS assay is a colorimetric method used to assess the metabolic activity and viability of PBSCs and other cell populations.
The Spectra Optia is a specialized apheresis system that can efficiently collect and concentrate PBSCs from the peripheral blood for subsequent use in transplantation or other regenerative medicine applications.
By leveraging these tools and techniques, researchers can optimize their PBSC research workflows, leading to improved outcomes in stem cell-based therapies and regenerative medicine.